



Skyrizi in India

The CDSCO named-patient coordination pathway — indicative 2026

IMMUNOLOGY · PLAQUE PSORIASIS, PSA, CROHN'S, UC

The clinical situation

Skyrizi (risankizumab-rzaa) is a subcutaneous anti-IL-23 (p19) monoclonal antibody FDA-approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Manufactured by AbbVie. The induction-maintenance calendar is indication-specific: typical maintenance is 150 mg SC every 12 weeks after loading; IBD uses IV induction followed by SC maintenance. Pre-treatment workup covers TB, hepatitis B/C screening, vaccination status, and baseline infection review.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your dermatologist, rheumatologist, or gastroenterologist documents indication, severity, prior biologics, and Skyrizi rationale.
- 2 Baseline screening.** TB, hepatitis B/C, vaccinations, and infection review completed and documented per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, strength, calendar, and chain-of-custody commitment.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; your physician initiates therapy with ongoing IL-23-class monitoring.

Indicative economics

Reference US cash-pay range: USD 17,000–21,000 per quarterly Skyrizi maintenance dose (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from AbbVie authorised distribution.

Documentation. Physician kit tailored to CDSCO review, with IL-23 class safety annex. **Logistics.** Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through each quarterly cycle. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Skyrizi × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/skyrizi-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team